• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Baxter ticks up on Q4, 2018 beats

January 31, 2019 By Brad Perriello

BaxterBaxter (NYSE:BAX) beat Wall Street’s consensus forecast with both its fourth-quarter and full-year results, to tepid reaction from investors, who sent the healthcare giant’s share price up a hair today.

Deerfield, Ill.-based Baxter posted a return to black ink for the three months ended Dec. 31, 2018, logging profits of $348 million, or 65¢ per share, on sales growth of 2.4% to $2.84 billion compared with the same period in 2017. Adjusted to exclude one-time items, earnings per share were 78¢, a full nickel ahead of The Street, where analysts were looking for sales of $2.80 billion.

Full-year profits surged 126.5% to $1.62 billion, or $2.97 per share, on sales growth of 5.4% to $11.27 billion, compared with 2017. Adjusted 2018 EPS came in at $3.05, again 5¢ ahead of analysts, who were looking for a top line of $11.09 billion.

“Baxter continued building momentum in 2018, delivering solid top-line and strong bottom-line performance for the year,” chairman & CEO Joe Almeida said in prepared remarks. “Our focus on increased innovation, combined with our diverse portfolio, global footprint and unwavering financial discipline, helped us maintain our trajectory in a dynamic marketplace.

“Our ongoing business transformation will continue throughout 2019 as we prepare to launch new products, pursue high-value capital deployment opportunities and deliver on additional operational excellence initiatives. Our goal remains to drive top quartile performance for all stakeholders in line with our mission to save and sustain lives,” Almeida said.

Baxter said it expects to report adjusted 2019 EPS of $3.22 to $3.30 on constant-currency sales growth of 2% to 3%. First-quarter adjusted EPS are pegged at 66¢ to 68¢ per share, on constant-currency sales growth of 1%, the company said.

BAX shares were up 0.9% to $72.34 apiece today in mid-day trading.

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Baxter

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS